Humacyte, Inc. Research and Development Expense
Humacyte, Inc. (HUMA) reported Research and Development Expense of $18.14 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- Humacyte, Inc. research and development expense for the quarter ending 2026-06-30 was $18.14M, a 17.55% decline year-over-year.
- Humacyte, Inc. research and development expense for the quarter ending 2026-03-31 was $19.46M, a 26.23% increase year-over-year.
- Humacyte, Inc. research and development expense for the quarter ending 2025-12-31 was $14.61M, a 29.29% decline year-over-year.
- Humacyte, Inc. research and development expense for the quarter ending 2025-09-30 was $17.27M, a 24.66% decline year-over-year.
- Humacyte, Inc. research and development expense for fiscal 2025 was $69.30M, a 21.78% decline from fiscal 2024.
- Humacyte, Inc. research and development expense for fiscal 2024 was $88.60M, a 15.74% increase from fiscal 2023.
- Humacyte, Inc. research and development expense for fiscal 2023 was $76.55M, a 21.01% increase from fiscal 2022.
- Humacyte, Inc. research and development expense for fiscal 2022 was $63.26M, a 3.13% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.14M 10-Q · filed 2026-08-12 | $37.61M 10-Q · filed 2026-08-12 | $52.21M derived: sum of 3 quarters · filed 2026-08-12 | $69.48M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $19.46M 10-Q · filed 2026-05-13 | $34.07M derived: sum of 2 quarters · filed 2026-05-13 | $51.34M derived: sum of 3 quarters · filed 2026-05-13 | $73.35M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $14.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $31.88M derived: sum of 2 quarters · filed 2026-03-27 | $53.88M derived: sum of 3 quarters · filed 2026-08-12 | $69.30M 10-K · filed 2026-03-27 |
| 2025-09-30 | $17.27M 10-Q · filed 2025-11-12 | $39.28M derived: sum of 2 quarters · filed 2026-08-12 | $54.70M 10-Q · filed 2025-11-12 | $75.35M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $22.01M 10-Q · filed 2026-08-12 | $37.42M 10-Q · filed 2026-08-12 | $58.08M derived: sum of 3 quarters · filed 2026-08-12 | $81.01M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $15.42M 10-Q · filed 2026-05-13 | $36.07M derived: sum of 2 quarters · filed 2026-05-13 | $59.00M derived: sum of 3 quarters · filed 2026-05-13 | $82.75M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $20.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $43.58M derived: sum of 2 quarters · filed 2026-03-27 | $67.33M derived: sum of 3 quarters · filed 2026-03-27 | $88.60M 10-K · filed 2026-03-27 |
| 2024-09-30 | $22.93M 10-Q · filed 2025-11-12 | $46.68M derived: sum of 2 quarters · filed 2025-11-12 | $67.94M 10-Q · filed 2025-11-12 | $88.12M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $23.75M 10-Q · filed 2025-08-11 | $45.02M 10-Q · filed 2025-08-11 | $65.20M derived: sum of 3 quarters · filed 2025-08-11 | $83.75M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $21.26M 10-Q · filed 2025-05-13 | $41.44M derived: sum of 2 quarters · filed 2025-05-13 | $60.00M derived: sum of 3 quarters · filed 2025-05-13 | $80.54M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $20.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $38.73M derived: sum of 2 quarters · filed 2025-03-31 | $59.27M derived: sum of 3 quarters · filed 2025-03-31 | $76.55M 10-K · filed 2025-03-31 |
| 2023-09-30 | $18.55M 10-Q · filed 2024-11-08 | $39.09M derived: sum of 2 quarters · filed 2024-11-08 | $56.37M 10-Q · filed 2024-11-08 | $71.33M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $20.54M 10-Q · filed 2024-08-13 | $37.82M 10-Q · filed 2024-08-13 | $52.77M derived: sum of 3 quarters · filed 2024-08-13 | $70.11M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $17.28M 10-Q · filed 2024-05-13 | $32.23M derived: sum of 2 quarters · filed 2024-05-13 | $49.57M derived: sum of 3 quarters · filed 2024-05-13 | $64.22M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $14.96M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $32.29M derived: sum of 2 quarters · filed 2024-03-28 | $46.95M derived: sum of 3 quarters · filed 2024-03-28 | $63.26M 10-K · filed 2024-03-28 |
| 2022-09-30 | $17.34M 10-Q · filed 2023-11-09 | $31.99M derived: sum of 2 quarters · filed 2023-11-09 | $48.30M 10-Q · filed 2023-11-09 | $64.55M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $14.65M 10-Q · filed 2023-08-14 | $30.97M 10-Q · filed 2023-08-14 | $47.22M derived: sum of 3 quarters · filed 2023-08-14 | $62.60M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $16.31M 10-Q · filed 2023-05-12 | $32.56M derived: sum of 2 quarters · filed 2023-05-12 | $47.95M derived: sum of 3 quarters · filed 2023-05-12 | $62.52M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $16.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $31.64M derived: sum of 2 quarters · filed 2023-03-24 | $46.20M derived: sum of 3 quarters · filed 2023-03-24 | $61.34M 10-K · filed 2023-03-24 |
| 2021-09-30 | $15.39M 10-Q · filed 2022-11-10 | $29.95M derived: sum of 2 quarters · filed 2022-11-10 | $45.09M 10-Q · filed 2022-11-10 | $58.29M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $14.57M 10-Q · filed 2022-08-12 | $29.70M 10-Q · filed 2022-08-12 | $42.90M derived: sum of 3 quarters · filed 2022-08-12 | $57.60M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $15.14M 10-Q · filed 2022-05-13 | $28.34M derived: sum of 2 quarters · filed 2022-05-13 | $43.03M derived: sum of 3 quarters · filed 2022-05-13 | |
| 2020-12-31 | $13.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $27.89M derived: sum of 2 quarters · filed 2022-03-29 | $54.08M 10-K · filed 2022-03-29 | |
| 2020-09-30 | $14.69M 10-Q · filed 2021-11-15 | $40.88M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |